Poly Medicure Share Price Today | Stock Price & Poly Medicure Share Screener
As of November 18, 2026, the live Poly Medicure share price (NSE: POLYMED) is ₹1,654.50 on NSE and ₹1,652.85 on BSE, up 0.30% from the previous close, with shares trading between ₹1,640.10 and ₹1,686.20 in today's trading session, and a 52-week range of ₹1,191.10–₹1,967.40. Track Poly Medicure market cap to gauge the company's total market size. Use the Poly Medicure stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Poly Medicure opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹554 and net income of ₹65, with EBITDA of ₹130, an operating margin of 21.0% and a profit margin of 11.7%.
Poly Medicure Share Price Chart
Track the current stock price of Poly Medicure with an interactive chart. Analyse POLYMED share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Poly Medicure stock quote in one place.
The quote of ₹1,654.50 sits between the 52-week low of ₹1,191.10 and the 52-week high of ₹1,967.40, and the latest session moved 0.30% from the previous close.
Poly Medicure Company Profile - Fundamental Screener
Screen Poly Medicure company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for POLYMED shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Healthcare Equipment & Supplies industry, with Devendra Raj Mehta listed as chairperson or CEO, and it trades under ISIN INE205C01021.
Business Overview
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and...more
Company Details
Classification
Identifiers and Leadership
Poly Medicure Balance Sheet Screener
Screen POLYMED balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹3,919, up from ₹3,193 in 2025.
Latest statistics put total assets at ₹3,919 and shareholder funds at ₹3,149, with a leverage ratio of 0.09.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 3,919 | 3,193 | 1,859 | 1,577 | 1,377 | 1,224 | 767 | 654 | 565 | 457 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 1,694 | 1,084 | 867 | 635 | 488 | 426 | 363 | 306 | 265 | 207 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 194 | 57 | 37 | 42 | 63 | 87 | 135 | 119 | 104 | 72 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 3,149 | 2,766 | 1,470 | 1,242 | 1,088 | 966 | 435 | 381 | 338 | 272 |
| Share Capital | 51 | 51 | 48 | 48 | 48 | 48 | 44 | 44 | 44 | 44 |
| Reserves & Surplus | 3,056 | 2,715 | 1,422 | 1,194 | 1,040 | 918 | 391 | 337 | 294 | 227 |
Poly Medicure Income Statement Screener - Profit & Revenue Analysis
Screen Poly Medicure income statement and profit fundamentals. Analyze POLYMED quarterly results. Poly Medicure reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹554 and net profit was ₹65, equal to earnings per unit of ₹6.54, at an operating margin of 21%.
In that period expenses were ₹424, interest cost ₹6 and tax ₹20. The next period listed, 2026-Jun, shows revenue of ₹560 and net profit of ₹85.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 554 | 560 | 611 | 467 | 447 | 479 | 522 | 393 | 402 | 447 | 448 | 316 | 335 | 352 | 357 |
| Expenses | 424 | 400 | 443 | 321 | 298 | 329 | 389 | 282 | 281 | 305 | 310 | 224 | 234 | 253 | 249 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 130 | 160 | 168 | 146 | 149 | 150 | 132 | 112 | 121 | 142 | 138 | 92 | 101 | 99 | 108 |
| Operating Profit % | 21.00% | 24.00% | 24.00% | 27.00% | 26.00% | 26.00% | 21.00% | 26.00% | 27.00% | 27.00% | 27.00% | 27.00% | 27.00% | 25.00% | 27.00% |
| Depreciation | 38 | 36 | 35 | 21 | 23 | 25 | 29 | 16 | 20 | 21 | 21 | 15 | 16 | 16 | 16 |
| Interest | 6 | 7 | 7 | 2 | 3 | 3 | 6 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 4 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 85 | 117 | 126 | 123 | 123 | 122 | 98 | 93 | 99 | 118 | 113 | 75 | 83 | 81 | 88 |
| Tax | 20 | 32 | 30 | 31 | 30 | 30 | 27 | 24 | 24 | 31 | 28 | 16 | 20 | 19 | 23 |
| Net Profit | 65 | 85 | 95 | 92 | 93 | 92 | 71 | 68 | 74 | 87 | 85 | 59 | 63 | 62 | 65 |
| EPS | 6.54 | 8.49 | 9.38 | 8.92 | 9.19 | 9.06 | 7.00 | 7.12 | 7.71 | 9.01 | 8.48 | 6.13 | 6.54 | 6.48 | 6.78 |
Poly Medicure Cash Flow Screener - Liquidity Fundamentals
Screen POLYMED cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹246, and net cash flow was an inflow of ₹43.
Over the same period, investing activities used ₹224 and financing activities provided ₹20.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 246 | 233 | 266 | 191 | 124 | 119 | 131 | 107 | 75 | 56 |
| Investing Activities | -224 | -1,187 | -241 | -179 | -85 | -436 | -110 | -101 | -88 | -56 |
Financing and Net Cash | ||||||||||
| Financing Activities | 20 | 951 | -20 | -13 | -35 | 317 | -21 | -5 | 16 | 0 |
| Net Cash Flow | 43 | -3 | 5 | -1 | 3 | 0 | 1 | 1 | 3 | 0 |
Poly Medicure Shareholding Pattern Screener
See Poly Medicure shareholding pattern with promoter, FII, and DII holdings. Check Poly Medicure promoter holding and ownership changes for POLYMED on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 62.42%, foreign institutions 5.91%, domestic institutions 15.59% and the public 12.61%, spread across 73,414 shareholders.
The shareholder count was 73,414 in 2026-Mar, compared with 73,643 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 62.42% | 62.42% | 62.42% | 62.44% | 62.44% | 62.42% | 62.42% | 53.15% |
Institutional Investors | ||||||||
| FII Holding | 5.91% | 5.57% | 5.35% | 11.46% | 11.41% | 9.77% | 9.40% | 12.38% |
| DII Holding | 15.59% | 16.08% | 15.90% | 11.96% | 11.72% | 13.54% | 13.84% | 7.22% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.61% | 12.18% | 12.31% | 11.08% | 11.37% | 11.25% | 11.30% | 11.34% |
| Other Holding | 3.47% | 3.76% | 4.02% | 3.07% | 3.07% | 3.02% | 3.04% | 15.92% |
| Shareholder Count | 73,414 | 73,643 | 74,153 | 65,583 | 71,142 | 64,400 | 67,750 | 36,712 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Poly Medicure. Poly Medicure dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹3.50 per unit for 2026-March, a yield of 0.21%, compared with ₹3.50 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹3.50, ₹3.50 and ₹3.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹3.50 | 0.21% |
| 2025-March | ₹3.50 | 0.29% |
| 2024-March | ₹3.00 | 0.13% |
| 2023-March | ₹3.00 | 0.19% |
| 2022-March | ₹2.50 | 0.27% |
| 2021-March | ₹2.50 | 0.26% |
| 2020-March | ₹2.00 | 0.24% |
| 2019-March | ₹2.00 | 0.86% |
| 2018-March | ₹2.00 | 0.91% |
| 2017-March | ₹2.50 | 1.00% |
Poly Medicure Stock Index Membership - Nifty & Sensex
See which indices include Poly Medicure stock. Check POLYMED index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 19 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
Poly Medicure Market Events Screener - Corporate Actions
Get Poly Medicure corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Poly Medicure stock events that may affect POLYMED share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Annual General Meeting dated September 5, 2026 and Dividend dated August 28, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | 7.56% |
| 2026-09-05 | 2026-09-05 | Annual General Meeting | NA | -6.19% |
| 2026-08-28 | 2026-08-29 | Dividend | ₹ 3.50 /share | 8.43% |
| 2026-08-07 | 2026-08-07 | Quarterly Result Announcement | NA | 2.33% |
| 2026-05-25 | 2026-05-25 | Quarterly Result Announcement | NA | -0.03% |
| 2026-02-05 | 2026-02-05 | Quarterly Result Announcement | NA | 0.14% |
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | -4.08% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -4.14% |
| 2025-09-18 | 2025-09-18 | Dividend | ₹ 3.50 /share | -22.75% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -6.11% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | -0.13% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -0.46% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | 2.58% |
| 2024-09-26 | 2024-09-26 | Annual General Meeting | NA | -7.22% |
| 2024-09-19 | 2024-09-20 | Dividend | ₹ 3.00 /share | 48.83% |
Poly Medicure Competitors Screener - Peer Stocks Comparison
Screen POLYMED competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Molbio Diagnostics | 17,129 | 121.60 | 1,455 | 41.57% | 164 | 60.75 |
| Poly Medicure | 17,072 | 53.80 | 1,995 | 13.43% | 321 | 64.63 |
| Sahajanand Medical Technologies | 5,522 | 78.70 | 1,219 | 17.64% | 69 | 75.49 |
| Tarsons Products | 1,651 | 226.00 | 447 | 9.38% | 14 | 47.58 |
| Laxmi Dental | 1,099 | 34.60 | 286 | 18.15% | 26 | 57.90 |
| Q-Line Biotech | 1,026 | 20.40 | 347 | 7.89% | 56 | 30.31 |
| Hemant Surgical Industries | 936 | 51.00 | 238 | 112.99% | 18 | 63.65 |
| Vasa Denticity | 846 | 69.90 | 283 | 12.77% | 10 | 65.05 |
| Osel Devices | 656 | 23.40 | 295 | 57.88% | 29 | 50.35 |
| Fabtech Technologies | 609 | 17.50 | 431 | 28.40% | 38 | 53.39 |
Poly Medicure Company Announcements - News & Reports Screener
Screen POLYMED latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 15, 2026.
The next most recent announcements are dated November 13, 2026 and November 9, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-15 | Intimation For The Schedule Of Investors/Analysts Call/Meet. | - |
| 2026-11-13 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-09 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-08 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-05 | Intimation Of Revision Of Policies And/Or Code Of Conduct Of The Company | - |
| 2026-11-05 | Statement Of Deviation(S) Or Variation(S) If Any Of Utilization Of Proceeds Received From Qualified Institutions Placement (QIP). | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-05 | Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026 | - |
| 2026-11-05 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-10-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-29 | Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On 05Th November 2026 | - |
| 2026-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-24 | Intimation For The Schedule Of Investors/Analysts Call/Meet. | - |
| 2026-09-23 | Intimation For The Schedule Of Investors/Analysts Call/Meet. | - |
| 2026-09-21 | Intimation For The Schedule Of Investors/Analysts Call/Meet. | - |
| 2026-09-18 | Intimation For The Schedule Of Investors/Analysts Call/Meet. | - |
| 2026-09-07 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-05 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,654.50, within a 52-week range of ₹1,191.10 to ₹1,967.40. The P/E ratio is 53.80 and the P/B ratio is 5.21, with earnings per unit of ₹31.79. Market capitalisation stands at ₹17,072.31 Cr and the dividend yield is 0.21%. The company operates in the Healthcare sector, in the Healthcare Equipment & Supplies industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.